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Bacillus anthracis, the causative agent of anthrax, secretes three polypeptides, which form the bipartite lethal and edema toxins
(LT and ET, respectively). The common component in these toxins, protective antigen (PA), is responsible for binding to cellular
receptors and translocating the lethal factor (LF) and edema factor (EF) enzymatic moieties to the cytosol. Antibodies against PA
protect against anthrax. We previously isolated toxin-neutralizing variable domains of camelid heavy-chain-only antibodies
(VHHs) and demonstrated their in vivo efficacy. In this work, gene therapy with an adenoviral (Ad) vector (Ad/VNA2-PA)
(VNA, VHH-based neutralizing agents) promoting the expression of a bispecific VHH-based neutralizing agent (VNA2-PA),
consisting of two linked VHHs targeting different PA-neutralizing epitopes, was tested in two inbred mouse strains, BALB/cJ
and C57BL/6J, and found to protect mice against anthrax toxin challenge and anthrax spore infection. Two weeks after a single
treatment with Ad/VNA2-PA, serumVNA2-PA levels remained above 1g/ml, with some as high as 10 mg/ml. The levels were
10- to 100-fold higher and persisted longer in C57BL/6J than in BALB/cJ mice. Mice were challenged with a lethal dose of LT or
spores at various times after Ad/VNA2-PA administration. The majority of BALB/cJ mice having serumVNA2-PA levels of>0.1
g/ml survived LT challenge, and 9 of 10 C57BL/6J mice with serum levels of>1g/ml survived spore challenge. Our findings
demonstrate the potential for genetic delivery of VNAs as an effective method for providing prophylactic protection from an-
thrax. We also extend prior findings of mouse strain-based differences in transgene expression and persistence by adenoviral
vectors.
Bacillus anthracis produces two toxins, which are responsiblefor allowing the bacterium to establish disease and induce le-
thality in the host. Lethal toxin (LT) and edema toxin (ET) are
composed of three proteins: protective antigen (PA), lethal factor
(LF), and edema factor (EF). PA is a receptor-binding component
that transports LF (a protease) or EF (an adenylate cyclase) into
cells where they can manifest their catalytic activities through the
targeting of ubiquitous substrates. EF targets ATP and converts it
to cyclic AMP (cAMP), resulting in cellular dysfunction and
vascular events that can lead to lethality. LF cleaves the mito-
gen-activated protein kinase (MEK) family and rodent nucle-
otide-binding domain and leucine-rich repeat containing a py-
rin domain 1 (NLRP1) inflammasome sensors. LF plays an
important role in both early and late anthrax infection. Early in
infection, inactivation of the MEK proteins by cleavage leads to
the inhibition of a wide variety of innate immune cell re-
sponses, which allows the bacterium to evade the immune sys-
tem, divide, and disseminate. The cleavage of NLRP1 early in
infection in certain inbred rodents results in the activation of
the inflammasome, macrophage pyroptosis, and induction of
proinflammatory cytokines, which induce a protective im-
mune response. Thus, certain inbred mouse strains are resis-
tant to spore infection, while others are sensitive. Late in infec-
tion, high levels of both anthrax toxins in the blood induce
unknown vascular events that contribute to the death of the
host. The use of tissue-specific PA receptor knockout mice has
now identified target tissues for both toxins. While the mech-
anism of LT-induced death is unknown, the cardiovascular
system is clearly the important target, and PA acts as the “gate-
way” for all intoxication events (1).
PA is an 83-kDa polypeptide that binds to receptors expressed
in most tissues. It is then cleaved by cell surface proteases, such as
furin, to a 63-kDa form that rapidly oligomerizes. Heptamers or
octamers of PA form binding sites for LF and EF (for a review, see
reference 1). Because antibiotic treatment of B. anthracis infection
is not effective after the anthrax toxins have accumulated in the
blood, the targeting of PA is an important therapeutic approach
against the disease. Themajority of neutralizing antibodies against
PA act on the receptor-binding domain 4 and prevent toxin inter-
action with cells. More rarely, PA is neutralized through other
mechanisms (2).
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Alpacas, camels, and llamas are known to produce heavy-
chain-only antibodies (for a review, see references 3 and 4). Vari-
able domains of camelid heavy-chain-only antibodies (VHHs)
can be expressed as recombinant proteins, which bind to antigen
with affinity similar to that of the whole antibody (Ab), but they
also have beneficial features, which include resistance to high tem-
perature and pH and the ability to access conformational epitopes
in folded structures, which are not generally reached by conven-
tional antibodies (3, 4). Our laboratories have established the effi-
cacy of VHHs against a variety of toxins (5–11). Linking of two or
more neutralizing VHHs that target different epitopes creates VHH-
based neutralizing agents (VNAs), which have proven to be greatly
improved antitoxin agents compared to a pool of their component
monomers (8–10, 12).Wepreviously characterizedapotentVNAfor
the treatment of anthrax (VNA2-PA), made as a heterodimer of two
VHHs that neutralize PA by differentmechanisms. OneVHH, JKH-
C7, inhibits the translocation of the cell surface-generated PA63 oli-
gomer, while the other, JIK-B8, is a potent receptor blocker with a
subnanomolar binding affinity for PA (6).
Gene therapy for in vivo expression of antibodies has had some
success (13–17). In this work, we used a recombinant replica-
tion-incompetent human adenovirus serotype 5 (Ad5) vector
that promotes expression and secretion into the serum of the
VNA (Ad/VNA2-PA), thereby passively immunizing the mice.
We measured antibody (Ab) levels over an 8-week period fol-
lowing a single bolus injection of Ad/VNA2-PA. We performed
studies in two different inbred strains in parallel and found that
robust protective Ab levels were rapidly established in both
strains, but at significantly different levels, and then dissipated at
different rates. Challenge studies done at various times posttreat-
ment showed that mice having serum VNA levels of 1 g/ml
were protected from anthrax infection. Our results show the po-
tential for VNA gene therapy as an anthrax therapeutic.
MATERIALS AND METHODS
Ethics statement. The animal studies were done in accordance with pro-
tocols approved by the animal care and use committees at the National
Institute of Allergy and Infectious Diseases (NIAID) (protocols LPD8E
and LPD9E).
Toxins. Endotoxin-free PA and LF were purified from B. anthracis, as
previously described (18). LT is a combination of PA and LF, which are
always used in equal amounts. The LF used here is a recombinant protein
having anN-terminal sequence beginningwithHMAGG.The LT concen-
trations correspond to the concentration of each toxin protein (i.e., 100
g/ml LT is 100 g/ml PA plus 100 g/ml LF).
Spores. Spores were prepared from the nonencapsulated toxigenic B.
anthracis Ames 35 (A35) strain (19) by growth on nutrient broth-yeast
(NBY) sporulation agar at 37°C for 24 h, followed by 5 days at room
temperature. Plates were inspected by microscopy to verify sporulation,
spores were gently washed off with cold sterile water, and the plates un-
derwent four additional cycles of sterile water washes and centrifugation.
The preparations were then heat treated at 75°C for 1 h to kill any remain-
ing vegetative bacteria. Spore quantification was performed using a
Petroff-Hausser counting chamber (Hausser Scientific, Horsham, PA)
and verified by dilution plating.
Ad/VNA2-PA construction and preparation. The generation of re-
combinant replication-incompetent Ad5-based vectors was previously
described (20). Briefly, in a modification from the method of Mukherjee
et al. (7), pShCMV-JGf7 shuttle plasmid was used for subcloning the
VNA2-PA-coding sequence (6), under the control of the mammalian cy-
tomegalovirus (CMV) promoter and followed by the bovine growth hor-
mone poly(A) signal. A control vector, Ad/VNA-RT, was created in a
similar manner with the sequence from two VHHs against ricin A chain
(21). This control vector results in the secretion of a ricin-reactive Ab,
with no binding to PA. Both shuttle plasmids were linearized and em-
ployed for homologous recombination with pAdEasy-1 plasmid, and the
resultant plasmids containing viral genomes were validated by PCR, re-
striction analyses, and sequencing. The plasmidswere linearizedwith PacI
to release the inverted terminal repeats of the viral genomic DNA and
transfected into 293 cells to rescue replication-incompetent Ad/
VNA2-PA and Ad/VNA-RT. These Ad vectors were propagated in 911
cells, purified by centrifugation of CsCl gradients, and dialyzed, and the
titers were determined.
Adenovirus and monoclonal administration and bleeds. C57BL/6J
or BALB/cJ mice (female, 8 weeks old) were obtained from Jackson Lab-
oratory (BarHarbor,ME).Nonreplicative adenoviral vectorswere diluted
in sterile saline and injected intravenously (i.v.) in the tail (100l/mouse,
3 1010 or 1.21011 viral particles/study). In separate groups, BALB/cJ
mice were injected with anti-PA monoclonal 14B7 (100 g or 10 g/
mouse, i.v., 100l).Mice were bled by themandibular or tail vein route at
various days post-adenoviral vector administration, and serum was sepa-
rated using serum separator tubes (Sarstedt, Newton, NC).
SerumVNAormonoclonal antibodymeasurement by ELISAs. Lev-
els of the VNA2-PA or monoclonal 14B7 in serum were measured by
enzyme-linked immunosorbent assay (ELISA). Immulon 2 HB immuno-
assay 96-well flat-bottom plates (Thermo Scientific, Franklin, MA) were
coated with PA in phosphate-buffered saline (PBS) (10 g/ml) overnight
at room temperature. The plates were washed with PBS and blocked with
1% gelatin (100l/well; Bio-Rad, Hercules, CA) for 1 h. Serum from each
mouse was serially diluted in triplicate, incubated for 2 to 3 h, removed,
and washed 3 times with PBS-Tween (1 PBS plus 0.05%Tween 20). For
sera from mice receiving adenoviral vector injections, a horseradish per-
oxidase (HRP)-conjugated anti-E-tag monoclonal antibody (MAb)
(Bethyl Laboratories, Montgomery, TX) was added to each well at 1:3,000
dilution, incubated for 2 h, andwashed 5 timeswith PBS-Tween. Formice
receiving 14B7 injections, a higher percentage (1.3%) of Tween 20 was
used in the washes, and an HRP-conjugated anti-mouse secondary anti-
body (Santa Cruz BT, Santa Cruz, CA) was used at 1:4,000. HRP substrate
reagent (R&D Systems, Minneapolis, MN), made of a combination of
stabilized hydrogen peroxidemixedwith stabilized tetramethylbenzidine,
was used for colorimetric assessment of HRP activity by spectrometry
(450 nM). Purified VNA2-PA or 14B7 dilutions were used to construct
standard curves, and Ab concentrations were calculated relative to these
curves using the GraphPad Prism software.
Toxin and spore challenge.Mice were challenged with lethal doses of
LT or spores at various times following adenovirus administration. Toxin
challenges were performed in BALB/cJ mice, which are known to be LT
sensitive but are spore resistant, due to harboring an LT-responsive
Nlrp1b locus (22). Spore challenges were performed in the spore-sensitive
C57BL/6J strain, which harbors a nonresponsive locus. LT (100 g/
mouse) was injected intraperitoneally (i.p.) (500 l), while spores (5 
107 A35 spores/mouse) were injected subcutaneously (s.c.) (200l) in the
scruff of the neck. Mice were monitored for signs of malaise and survival
twice daily for 7 days following infection.
RESULTS
We tested the efficacy of in vivo adenoviral production of het-
erodimeric anti-PA VNA2-PA by injecting BALB/cJ (n 15) and
C57BL/6J (n  15) mice with 3  1010 viral particles of Ad/
VNA2-PA and the same number ofmice with a control adenoviral
vector (Ad/VNA-RT) that produces an antiricinAbnot reactive to
PA. The i.v. route was selected for the administration of vector, as
earlier studies with a similar adenoviral vector expressing an anti-
botulinum toxin VNA showed 6- to 7-fold-higher VNA levels fol-
lowing i.v. versus i.p. injections, and a benefit of30-fold over the
s.c. route (7). All mice were bled on day 10 and anti-PAVNA titers
assessed. BALB/cJ mice had anti-PA VNA concentrations ranging
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from 0.9 g/ml to 2.3 mg/ml, with an average concentration of
419 g/ml and a median concentration of 35 g/ml. These levels
were far lower than the 6.2 mg/ml average concentration (7.03
mg/ml median) measured for C57BL/6J mice (Fig. 1A). This is
likely due to the fact that BALB/c inbred mice eliminate cells con-
taining the Ad transgene much more rapidly than do C57BL/6
mice (23, 24). While 4 of 15 BALB/cJ mice had milligram per
milliliter levels of VNA, the rest had levels of 1 to 100 g/ml. The
lowest level of VNA in C57BL/6J mice was 1 mg/ml, with the
majority of mice having between 5 and 10 mg/ml VNA (Fig. 1A).
Fivemice from each strainwere challenged in a blinded fashion on
day 11. BALB/cJ mice were challenged i.p. with the 100% lethal
dose (LD100) of anthrax LT (100 g), while spore-sensitive
C57BL/6Jmice were challengedwith 5 LD100 of 5 10
7 spores. All
mice treated with the Ad/VNA2-PA survived, while all challenged
controls that had been treated with control vector succumbed
(Fig. 1B and C).
VNA2-PA serum levels were again assessed on day 18 for all
mice and were found to be reduced but to very different levels in a
mouse strain-dependent manner. In BALB/cJ mice, 11/15 mice
had levels of1g/ml, while all C57BL/6J mice had titers of10
g/ml (Fig. 2A), as is discussed below. Because protection against
FIG 1 Day 10 serum analyses and day 11 challenge studies. (A) Groups of BALB/cJ or C57BL/6J mice (n  15/group) were injected with Ad/VNA2-PA or
Ad/VNA-RT (3  1010 viral particles), and VNA2-PA levels were assessed on day 10. Each circle refers to a single mouse, with the upper panel showing
Ad/VNA2-PA groups and the lower panel showing the control vector groups. The dashed lines indicate the average (black) andmedian (red) Ad/VNA2-PA levels
for each strain. The gray boxes indicate the mice that were challenged, with results shown in panels B and C. (B) BALB/cJ mice treated with Ad/VNA2-PA and
controlmice (n 5/group; see panel A)were challenged on day 11with LT (100g, i.p.) andmonitored formalaise and survival. (C) C57BL/6Jmice treatedwith
Ad/VNA2-PA and control mice (n 5/group; see panel A) were challenged with anthrax A35 spores (5 107 spores/mouse) and monitored for malaise and
survival.
FIG 2 Day 18 serum analyses and day 19 challenge study results. (A) Day 18 sera from the mice that survived challenge and unchallenged mice described in Fig.
1 were analyzed for VNA2-PA levels. Each circle refers to a single mouse, with the upper panel showing Ad/VNA2-PA groups and the lower panel showing the
control vector groups. The gray boxes indicate the two groups of 10 BALB/cJ mice that were challenged, with the results shown in panel B. The filled rectangles
indicate the absence of sera formice that succumbed in a previous challenge. The dashed lines indicate the average (black) andmedian (red) Ad/VNA2-PA levels
for each strain. D, dead (5 mice that succumbed to the challenge described in panel B). (B) BALB/cJ mice treated with Ad/VNA2-PA and control mice (n 
10/group; see panel A) were challenged on day 19 with LT (100 g, i.p.) and monitored for malaise and survival.
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LT bolus challenge has historically required bolus administration
of at least 50g of neutralizingMAb, we challenged the remaining
BALB/cJ mice (n 10) with the LD100 of LT on day 19. Of the 10
challenged mice, 50% survived challenge (Fig. 2B). It appeared
that mice with VNA levels of 1 g/ml (18.6 nM) survived,
with one exception, while mice with levels of 0.1 g/ml (1.8
nM) were not protected from this dose of toxin. Since VNA levels
as low as10% (mol/mol) that of injected toxin were sufficient to
save mice, this suggested that the majority of the toxin in the
100-gmouse challenge had been cleared or processed or was not
functionally relevant for lethality. Not surprisingly, all mice
treated with control vector succumbed to toxin. To compare this
protection threshold with that which is required for protection
with the well-characterized anti-PA MAb 14B7, we assessed the
levels of 14B7 in circulation after bolus challenge (Fig. 3A). A
bolus of 100 g of monoclonal 14B7 is fully protective (Fig. 3B),
and this dose produced circulatingMAb levels of 4 to 21g/ml (25
to 135 nM) when assessed at the time of toxin challenge, 2 h after
MAb administration (Fig. 3A). A bolus of 10 g/ml 14B7 was not
protective (Fig. 3B), although levels of MAb in circulation ranged
from 0.87 to 2.3 g/ml (5.6 to 14.83 nM) at the time of challenge
(Fig. 3A). It may be that VNA2-PA from gene therapy is slightly
more efficient than 14B7 in toxin neutralization in vivo, possibly
due to broader systemic distribution or access to tissue sites un-
available to 14B7. Overall, the protective threshold for an LD100
LT challenge when employing a potent antitoxin Ab appears to be
18 to 25 nM.
The C57BL/6J mice, which retained high levels of VNA2-PA at
18 days, were again monitored on days 25 and 33 post-Ad vector
administration. There was a gradual drop in VNA levels over this
period, with mice having a wide range of concentrations,
from 0.1 to 10 g/ml on day 33 (Fig. 4A). The control mice
treated with Ad/VNA-RT had no detectable anti-PA VNA signal
on day 25 or 33 (data not shown).When all the remaining unchal-
lenged C57BL/6J mice (n  10) were challenged with anthrax
spores (5 LD100 [5  10
7 spores/mouse]) on day 34, there was a
substantial delay in the onset of malaise and death in the mice
treated with Ad/VNA2-PA, and 40% of challenged mice survived
(Fig. 4B). Mice with VNA levels of 1 g/ml (18.6 nM) died.
These results suggest that the levels of serumVNA2-PA antibodies
that are protective in spore challenges of C57BL/6J mice are sim-
ilar to the levels needed for the protection of BALB/cJmice against
lethal toxin challenge.
In a second study, we transduced BALB/cJ mice with a higher
number of viral particles (1.2 1011 particles/mouse) and found
that the levels of VNA2-PA were consistently higher than those in
the first study, even at 2 weeks after vector administration, with all
mice at 100 g/ml and 3/16 mice at 1 mg/ml (Fig. 5). By 4
weeks, however, the levels of VNA for all mice had dropped pre-
FIG 3 14B7 levels in sera and LT challenge outcome. (A) BALB/cJ mice (n
5/group) were injected with either 10 or 100g ofMAb 14B7 (i.v., 100l) and
bled at 2 h to assess circulating levels of PA-specificmonoclonal antibody. The
solid line indicates the average MAb serum level. (B) All mice from panel A
were challenged with LT (100 g, i.p.) 2.5 h after MAb administration. The
mice were monitored for a week for signs of malaise.
FIG 4 Day 25 and 33 serum analyses and day 34 spore challenge study results. (A) Comparison of day 18 serum VNA2-PA levels from Fig. 2 shown with levels
on day 25 and 33. The dashed line indicates the average Ad/VNA2-PA levels for the 10 C57BL/6Jmice on day 33. The box indicates themice that were challenged
on day 34. D, dead (6mice that succumbed to the challenge described in panel B). (B) C57BL/6Jmice treatedwithAd/VNA2-PA and controlmice (n 10/group;
see panel A) were challenged on day 34with anthrax A35 spores (5 107 spores/mouse) andmonitored formalaise and survival. Error bars indicate the standard
deviation in multiple measurements from a single mouse.
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cipitously to the range of 0.1 to 1 g/ml, indicating that the rela-
tive net loss of VNA in BALB/cJ mice occurred in proportion to
the initial starting concentration but at a similar pace, indepen-
dent of vector dose. Not surprisingly, only 3 of 16mice challenged
with LT survived.
DISCUSSION
We tested the ability of an Ad5-based adenoviral vector (Ad/
VNA2-PA) expressing a bispecific VHH-based neutralizing agent
(VNA2-PA) consisting of two linked VHHs targeting different
anthrax toxin PA-neutralizing epitopes to protect mice against
anthrax toxin challenge and anthrax spore infection. A single
treatment with Ad/VNA2-PA resulted in antibody levels as high as
10 mg/ml. Levels were higher and persisted longer in C57BL/6J
than in BALB/cJ mice. LT-sensitive BALB/cJ mice having serum
VNA2-PA levels of 0.1 g/ml typically survived LT challenge,
and spore-sensitive C57BL/6J mice with levels of1 g/ml typi-
cally survived spore challenge. The studies presented here indicate
that adenoviral delivery of VNAs can provide an excellent alterna-
tive to standard antibody therapeutics. Sustained levels of VNA
with a single administration of nonreplicative Ad5 allows the host
to combat the effects of toxin or virulence factors for longer peri-
ods than repeated administration of purified antibody. Further-
more, the gene therapy vectors can be used as prophylactic thera-
peutics if there is a danger of exposure of large populations to toxic
agents. The VHH-based therapeutics can also be engineered to
make VNAs that target multiple toxins or agents in a single prod-
uct, delivered with a single inoculation (9). These vectors also
allow the possibility to deliver VNAs to specific tissue sites
through vector engineering (25).While Ad5 vector use in humans
might be limited by widespread preexisting immunity, alternative
gene therapy vectors, such as adenoviruses from simian sources or
adeno-associated viruses, are being developed and may prove
more practical for general use.
Interestingly, the levels of VNA in our current studies were not
sustained for as long a period as those observed for a similarly
constructed anti-botulinum antitoxin VNA, which was delivered
i.v. at 3  1010 viral particles into CD-1 Swiss mice (7). In that
study, VNA levels remained at 1 to 10mg/ml in half themice, even
at 8 weeks postinoculation, although some mice had significantly
lower levels as early as 10 days postinoculation. Thus, the range of
serum VNA might vary from 0.01 ng/ml to 100 g/ml in the
mice at 6 to 8 weeks after vector administration. The reason for
this is very likely the genetic heterogeneity of CD-1 mice, which
are outbred. Genetic factors have been reported to influence the
efficiency of Ad infection and/or transgene production (24, 26,
27), and it is not surprising that these factorswould bemore varied
in the outbred mice than observed within the two inbred lines
used in the current study. The same genetic factors are expected to
exist among humans and thus lead to differential responses to
various forms of antibody and VNA gene therapy.
Our findings that protection against anthrax toxin is possible
for weeks after a single administration of Ad/VNA2-PA suggest
that adenoviral antianthrax therapeutics are a viable option as
future therapeutic agents against this disease. The options to ad-
minister intranasal Ad/VNA2-PA vectors or administer paren-
teral Ad/VNA2-PA vectors designed to promote pulmonary VNA
expression (28) may result in even more effective therapeutics for
anthrax exposures. Future studies will focus on tissue-specific tar-
geting of VNA gene therapy vehicles for more efficient neutraliza-
tion of toxic effects at relevant disease sites.
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